A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC) (NCT07111520)
🩺 Plain-English Summary (8th-Grade Level)
This is a multi-site, open-label, dose-finding study, consisting of Parts 1, 2a, and 2b to investigate the combination of BNT326 with pumitamig (also known as BNT327 or PM8002) in participants with relapsed, progressive as well as treatment-naïve, advanced/metastatic non-small cell lung cancer (NSCLC). This study will enroll adult participants with histologically or cytologically confirmed NSCLC that is advanced (i.e., either metastatic or recurrent tumors with no known curative treatment available). The main goals of this study are: 1. To find the best dose levels (DLs) for the combination of BNT326 and pumitamig. 2. To look at how well participants with advanced NSCLC tolerate the combination therapy (for example, which side effects participants experience and how severe they are). 3. To look at how well the combination therapy works to shrink the tumor in participants with advanced NSCLC.
Who can join: Review the eligibility criteria below.
Location: UCLA Hematology Oncology - Main Site — Los Angeles, California
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (85 Sites)
- UCLA Hematology Oncology - Main Site — Los Angeles, California
- Stanford Cancer Institute — Stanford, California
- Yale University — New Haven, Connecticut
- Georgetown University - Lombardi Comprehensive Cancer Center — Washington D.C., District of Columbia
- Moffit Cancer Center — Tampa, Florida
- Dana-Farber Cancer Institute — Boston, Massachusetts
- Henry Ford Health System — Detroit, Michigan
- Memorial Sloan Kettering Cancer Center — New York, New York
- Cleveland Clinic Taussig Cancer Institute Case Comprehensive Cancer Center — Cleveland, Ohio
- University of Texas M. D. Anderson Cancer Center — Houston, Texas
- NEXT Virginia — Fairfax, Virginia
- Cancer Research SA — Adelaide,
- St George Private Hospital — Kogarah,
- Royal North Shore Hospital — Saint Leonards,
- Mater — South Brisbane,
- John Flynn Private Hospital — Tugun,
- Westmead Hospital — Westmead,
- Affiliated Hospital of Hebei University — Baoding,
- Beijing GoBroad Hospital — Beijing,
- The First Hospital of Jilin University — Changchun,
- West China Hospital, Sichuan University — Chengdu,
- Chongqing University Cancer Hospital — Chongqing,
- Fujian Provincial Cancer Hospital — Fuzhou,
- The First Affiliated Hospital School of Clinical Medicine of Guangdong Pharmaceutical University — Guangzhou,
- The First Affiliated Hospital of Guangzhou Medical University — Guangzhou,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.